Acrivon Therapeutics(US:ACRV) Globenewswire·2026-01-23 13:11Core Insights - Acrivon Therapeutics is set to present interim clinical data for ACR-368, a treatment for endometrial cancer, at the ESGO 27 Annual Congress in February 2026, highlighting its potential in a high unmet need patient population [1][2] Company Overview - Acrivon Therapeutics is a clinical stage biotechnology company focused on precision medicine, utilizing its proprietary Generative Phosphoproteomics AP3 platform for drug discovery and development [5] - The AP3 platform enables the interpretation and quantification of drug-regulated effects in intact cells, providing actionable insights and overcoming limitations of traditional drug discovery methods [5] Clinical Development - ACR-368, also known as prexasertib, is a selective small molecule inhibitor targeting CHK1 and CHK2, currently in a potentially registrational Phase 2 trial for endometrial cancer [6] - The FDA has granted Fast Track designation for ACR-368 as a monotherapy based on OncoSignature-predicted sensitivity in endometrial cancer patients, along with Breakthrough Device designation for the ACR-368 OncoSignature assay [6] Pipeline Programs - Acrivon is advancing ACR-2316, a selective WEE1/PKMYT1 inhibitor, which has shown promising initial clinical activity and a favorable tolerability profile in Phase 1 trials [8] - The company is also developing ACR-6840, targeting CDK11, as part of its internally discovered pipeline programs [8]